PDE3A mutations cause autosomal dominant hypertension with brachydactyly

Nature Genetics

Volumn 47, Issue 6, 2015, Pages 647-653

  Maass, Philipp G ^a,ag   Aydin, Atakan ^a   Luft, Friedrich C ^a,b   Schächterle, Carolin ^a   Weise, Anja ^c   Stricker, Sigmar ^d,e   Lindschau, Carsten ^f,g   Vaegler, Martin ^a,h   Qadri, Fatimunnisa ^a   Toka, Hakan R ^i,j   Schulz, Herbert ^a,k   Krawitz, Peter M ^d,l   Parkhomchuk, Dmitri ^d,l   Hecht, Jochen ^d,l   Hollfinger, Irene ^a   Wefeld Neuenfeld, Yvette ^a   Bartels Klein, Eireen ^a   Mühl, Astrid ^a   Kann, Martin ^m   Schuster, Herbert ⁿ   Chitayat, David ^o,p   Bialer, Martin G ^q   Wienker, Thomas F ^d,r   Ott, Jürg ^s,t   Rittscher, Katharina ^c   Liehr, Thomas ^c   Jordan, Jens ^f   Plessis, Ghislaine ^u   Tank, Jens ^f   Mai, Knut ^a   Naraghi, Ramin ^v   Hodge, Russell ^a   Hopp, Maxwell ^w   Hattenbach, Lars O ^x   Busjahn, Andreas ^y   Rauch, Anita ^z   Vandeput, Fabrice ^aa,ab,ac   Gong, Maolian ^a   Rüschendorf, Franz ^a   Hübner, Norbert ^a,l,ad   Haller, Hermann ^f   Mundlos, Stefan ^d,l   Bilginturan, Nihat ^ae   Movsesian, Matthew A ^aa,ab,ac   Klussmann, Enno ^a,ad   Toka, Okan ^af   Bähring, Sylvia ^a   more..

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g Staatliche Technikerschule Berlin   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF COLOGNE   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ INFOGEN   (Germany)

^o HOSPITAL FOR SICK CHILDREN   (Canada)

^p MOUNT SINAI HOSPITAL   (Canada)

^q Northwell Health   (United States)

^r UNIVERSITY OF BONN   (Germany)

^s INSTITUTE OF PSYCHOLOGY   (China)

^t ROCKEFELLER UNIVERSITY   (United States)

^u CAEN UNIVERSITY HOSPITAL   (France)

^v BUNDESWEHRKRANKENHAUS ULM   (Germany)

^w Griffith Base Hospital   (Australia)

^x KLINIKUM LUDWIGSHAFEN   (Germany)

^y HealthTwist GmbH   (Germany)

^z UNIVERSITY OF ZURICH   (Switzerland)

^aa VETERANS AFFAIRS MEDICAL CENTER   (United States)

^ab UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^ac UNIVERSITY OF UTAH   (United States)

^ad DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^ae HACETTEPE UNIVERSITY   (Turkey)

^af UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ag Harvard University   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PDE3A PROTEIN, HUMAN; PHOSPHODIESTERASE III;

ADOLESCENT; ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT HYPERTENSION WITH BRACHYDACTYLY; AUTOSOMAL DOMINANT INHERITANCE; BLOOD PRESSURE REGULATION; BRACHYDACTYLY; CARTILAGE CELL; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; ESSENTIAL HYPERTENSION; FEMALE; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MUTATOR GENE; PHOSPHODIESTERASE 3A GENE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; ROSTRAL VENTROLATERAL MEDULLA; SCHOOL CHILD; SKIN FIBROBLAST; VASCULAR SMOOTH MUSCLE CELL; AMINO ACID SEQUENCE; ANIMAL; CASE CONTROL STUDY; CELL DIFFERENTIATION; GENETICS; HYPERTENSION; KINETICS; MESENCHYMAL STROMA CELL; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PEDIGREE; PHYSIOLOGY; SMOOTH MUSCLE FIBER;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BRACHYDACTYLY; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHILD; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FEMALE; GENETIC ASSOCIATION STUDIES; HELA CELLS; HUMANS; HYPERTENSION; KINETICS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; MYOCYTES, SMOOTH MUSCLE; PEDIGREE;

EID: 84930065286     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3302     Document Type: Article

References (55)

1. Hunter, D.J. & Reddy, K.S. Noncommunicable diseases. N. Engl. J. Med. 369, 1336-1343 (2013).
2. Schuster, H. et al. Severe autosomal dominant hypertension and brachydactyly in a unique Turkish kindred maps to human chromosome 12. Nat. Genet. 13, 98-100 (1996).
3. Schuster, H. et al. A cross-over medication trial for patients with autosomal-dominant hypertension with brachydactyly. Kidney Int. 53, 167-172 (1998).
4. Naraghi, R. et al. Neurovascular compression at the ventrolateral medulla in autosomal dominant hypertension and brachydactyly. Stroke 28, 1749-1754 (1997).
5. Lifton, R.P. Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect. 100, 71-101 (2004).
6. Bilginturan, N., Zileli, S., Karacadag, S. & Pirnar, T. Hereditary brachydactyly associated with hypertension. J. Med. Genet. 10, 253-259 (1973).
7. Toka, O. et al. Childhood hypertension in autosomal-dominant hypertension with brachydactyly. Hypertension 56, 988-994 (2010).
8. Bähring, S. et al. Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension 43, 471-476 (2004).
9. Bähring, S. et al. Inversion region for hypertension and brachydactyly on chromosome 12p features multiple splicing and noncoding RNA. Hypertension 51, 426-431 (2008).
10. Gong, M. et al. Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. Hum. Mol. Genet. 12, 1273-1277 (2003).
11. Maurice, D.H. et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64, 533-546 (2003).
12. Wakabayashi, S. et al. Involvement of phosphodiesterase isozymes in osteoblastic differentiation. J. Bone Miner. Res. 17, 249-256 (2002).
13. Michot, C. et al. Exome sequencing identifes PDE4D mutations as another cause of acrodysostosis. Am. J. Hum. Genet. 90, 740-745 (2012).
14. Lee, H. et al. Exome sequencing identifes PDE4D mutations in acrodysostosis. Am. J. Hum. Genet. 90, 746-751 (2012).
15. Maass, P.G. et al. A misplaced lncRNA causes brachydactyly in humans. J. Clin. Invest. 122, 3990-4002 (2012).
16. Insel, P.A., Stengel, D., Ferry, N. & Hanoune, J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J. Biol. Chem. 257, 7485-7490 (1982).
17. Knowles, R.G., Palacios, M., Palmer, R.M. & Moncada, S. Formation of nitric oxide from l-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl. Acad. Sci. USA 86, 5159-5162 (1989).
18. Wechsler, J. et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J. Biol. Chem. 277, 38072-38078 (2002).
19. Vandeput, F. et al. Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. Proc. Natl. Acad. Sci. USA 110, 19778-19783 (2013).
20. Choi, Y.H. et al. Identifcation of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem. J. 353, 41-50 (2001).
21. Cone, J. et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34, 497-504 (1999).
22. Dunkerley, H.A. et al. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol. Pharmacol. 61, 1033-1040 (2002).
23. Linglart, A. et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N. Engl. J. Med. 364, 2218-2226 (2011).
24. Salem, H.K. & Thiemermann, C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28, 585-596 (2010).
25. Begum, N., Hockman, S. & Manganiello, V.C. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J. Biol. Chem. 286, 26238-26249 (2011).
26. Schuster, H. et al. Autosomal dominant hypertension and brachydactyly in a Turkish kindred resembles essential hypertension. Hypertension 28, 1085-1092 (1996).
27. Hunter, R.W., Mackintosh, C. & Hers, I. Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J. Biol. Chem. 284, 12339-12348 (2009).
28. Pozuelo Rubio, M., Campbell, D.G., Morrice, N.A. & Mackintosh, C. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem. J. 392, 163-172 (2005).
29. Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257, 7847-7851 (1982).
30. Graves, L.M. et al. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA 90, 10300-10304 (1993).
31. Zhao, H., Guan, Q., Smith, C.J. & Quilley, J. Increased phosphodiesterase 3A/4B expression after angioplasty and the effect on VASP phosphorylation. Eur. J. Pharmacol. 590, 29-35 (2008).
32. Song, G.J., Fiaschi-Taesch, N. & Bisello, A. Endogenous parathyroid hormone-related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells. Mol. Endocrinol. 23, 1681-1690 (2009).
33. Hundsrucker, C. et al. Glycogen synthase kinase 3β interaction protein functions as an A-kinase anchoring protein. J. Biol. Chem. 285, 5507-5521 (2010).
34. Beca, S. et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ. Res. 112, 289-297 (2013).
35. 2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 8, 1061-1067 (2007).
36. Ahmad, F. et al. Regulation of SERCA2 activity by PDE3A in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J. Biol. Chem. 290, 6763-6776 (2015).
37. Bassler, D., Kreutzer, K., McNamara, P. & Kirpalani, H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst. Rev. CD007802 (2010).
38. Pftzer, G. Invited review: regulation of myosin phosphorylation in smooth muscle. J. Appl. Physiol. 91, 497-503 (2001).
39. Klopocki, E. et al. Deletion and point mutations of PTHLH cause brachydactyly type E. Am. J. Hum. Genet. 86, 434-439 (2010).
40. Bastepe, M. et al. Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc. Natl. Acad. Sci. USA 101, 14794-14799 (2004).
41. Chilco, P.J., Leopold, V. & Zajac, J.D. Differential regulation of the parathyroid hormone-related protein gene P1 and P3 promoters by cAMP. Mol. Cell. Endocrinol. 138, 173-184 (1998).
42. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
43. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
44. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
45. Kamphans, T. & Krawitz, P.M. GeneTalk: an expert exchange platform for assessing rare sequence variants in personal genomes. Bioinformatics 28, 2515-2516 (2012).
46. Chen, K. et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 6, 677-681 (2009).
47. Spielmann, M. et al. Homeotic arm-to-leg transformation associated with genomic rearrangements at the PITX1 locus. Am. J. Hum. Genet. 91, 629-635 (2012).
48. Hofmann, N.A., Reinisch, A. & Strunk, D. Isolation and large scale expansion of adult human endothelial colony forming progenitor cells. J. Vis. Exp. 32, 1524 (2009).
49. Hundsrucker, C. et al. High-affnity AKAP7δ-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides. Biochem. J. 396, 297-306 (2006).
50. Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of diffcult sequences. Nat. Protoc. 2, 3247-3256 (2007).
51. Stefan, E. et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J. Am. Soc. Nephrol. 18, 199-212 (2007).
52. Schäfer, G. et al. Highly functionalized terpyridines as competitive inhibitors of AKAP-PKA interactions. Angew. Chem. Int. Edn Engl. 52, 12187-12191 (2013).
53. Christian, F. et al. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286, 9079-9096 (2011).
54. Aydin, A., Toliat, M.R., Bahring, S., Becker, C. & Nurnberg, P. New universal primers facilitate Pyrosequencing. Electrophoresis 27, 394-397 (2006).
55. Maass, P.G. et al. A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to Brachydactyly Type E. Hum. Mol. Genet. 19, 848-860 (2010).